Insulet Corporation filings document the financial, regulatory, governance, and operating disclosures of a medical device company built around the Omnipod tubeless insulin delivery platform. Current reports record quarterly and annual results, Omnipod revenue categories, U.S. and international performance, drug delivery revenue, and related financial-condition disclosures.
Insulet’s SEC filings also cover Regulation FD updates on product-quality and medical device correction matters, material supply agreements, stock repurchase authorizations, executive severance arrangements, auditor changes, and proxy governance. Its definitive proxy materials describe board oversight, executive compensation, leadership structure, and other shareholder-voting matters tied to the company’s public-company governance.
Insulet Corporation (PODD) Form 4 shows insider transactions by Laetitia Cousin, SVP, Regulatory, Quality & Compliance, dated 09/08/2025. The filing reports the acquisition of 541 shares via an employee stock option exercisable at $276.36 and 256 shares via a separate option exercisable at $166.62, both effective 09/08/2025. The reporting person also acquired 541 and 256 shares (reported as non-derivative acquisitions) at those prices and sold 797 shares on the same date at a weighted average price of $348.81. The filing discloses that 93 of the acquired shares were purchased under the company stock purchase plan since the last Section 16 filing. Following the reported transactions, beneficial ownership figures are shown as 4,431; 4,687; and 3,890 shares on the respective lines. The transactions include annual non-qualified option awards that vest in four substantially equal annual installments.
Insulet Corporation (PODD) filed a Form 144 reporting a proposed sale of 797 common shares through Fidelity Brokerage Services LLC on the NASDAQ with an aggregate market value of $278,000.26. The filing shows the shares were acquired via options granted by the issuer on 02/28/2023 (541 shares) and 02/27/2024 (256 shares) and that payment is noted as cash with an approximate sale date of 09/08/2025. No securities were reported sold by the filer in the past three months. The filer attests they are unaware of any undisclosed material adverse information about the issuer.
Insulet Corporation (PODD) Form 144 notifies of a proposed sale of 687 common shares through Fidelity Brokerage Services with an aggregate market value of $238,718.01, planned for 09/08/2025 on NASDAQ. The shares were acquired by the filer via restricted stock vesting as compensation on 01/10/2025 (308 shares) and 02/27/2025 (379 shares).
The filing also discloses prior sales by the same person, Prem Singh: 2,327 shares sold on 06/13/2025 for $698,216.35 and 1,343 shares sold on 08/07/2025 for $429,760.00. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
Benjamin Eric, Executive Vice President and Chief Product Experience Officer at Insulet Corporation (PODD), reported the sale of 4,263 shares of Insulet common stock on 08/21/2025 at a price of $332.23 per share. Following the transaction, he beneficially owns 16,736 shares. The Form 4 indicates the sale was made pursuant to an existing Rule 10b5-1 trading plan. The filing also notes that 93 shares were acquired through the company Employee Stock Purchase Plan since his last Form 4. The document is a routine Section 16 disclosure of an insider sale under a pre-established plan and does not disclose additional transactions, derivatives, or other compensatory details.
Michael R. Minogue, a director of Insulet Corporation (PODD), reported multiple transfers of common stock on 08/19/2025 and 08/21/2025. The Form 4 shows transfers described as coming from a GRAT and as bona fide gifts to a trust for the reporting person’s spouse, who is trustee. The filing lists several paired dispositions and acquisitions of 9,459 and 1,380 shares (transaction code G, gift/transfer). The report discloses post-transaction beneficial ownership amounts including 778 shares held directly and 15,453 shares held indirectly by trust, along with intermediate reported balances (e.g., 11,617, 14,073). The signature is by attorney-in-fact John W. Kapples dated 08/21/2025.
Insulet Corporation (PODD) Form 144 reports a proposed sale of 4,263 shares of common stock through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $1,416,296.49 and an approximate sale date of 08/21/2025. The filing shows the shares to be sold were recently acquired by the seller through restricted stock vesting on 02/14/2025 (2,842 shares), 02/27/2025 (806 shares), and 02/28/2025 (615 shares), with consideration recorded as compensation. No securities were reported sold by the same person in the prior three months. The filer attests they are not aware of any undisclosed material adverse information about the issuer.
Capital Research Global Investors reports beneficial ownership of 4,736,127 shares of Insulet Corporation, equal to 6.7% of the company's outstanding common stock. The filing shows sole voting power for 4,730,490 shares and sole dispositive power for 4,736,127 shares, with no shared voting or dispositive authority reported.
The statement classifies the filer as an investment adviser and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. This is a routine institutional ownership disclosure reflecting a material passive stake above the 5% threshold.
Insulet Corporation insider report: Prem Singh, SVP, Global Operations, reported multiple equity transactions dated 08/07/2025 involving common stock and stock options of Insulet (PODD). The Form 4 shows two acquisitions of common stock for 585 shares at $264.69 and 758 shares at $276.36, and a disposition of 1,343 shares sold at $320. The filing states these transactions were effected under an existing Rule 10b5-1 trading plan. The report also discloses annual non-qualified stock option awards: 585 options at a $264.69 exercise price (expiring 02/28/2032) and 758 options at a $276.36 exercise price (expiring 02/28/2033), each vesting in substantially equal installments over four years. The document lists line-by-line beneficial ownership figures corresponding to each transaction.